Xibrom FDA Approval History
FDA Approved: Yes (Discontinued) (First approved March 24, 2005)
Brand name: Xibrom
Generic name: bromfenac
Dosage form: Ophthalmic Solution
Company: Bausch & Lomb Inc.
Treatment for: Postoperative Ocular Inflammation
Marketing Status: Discontinued
Xibrom (bromfenac) is an ophthalmic nonsteroidal antiinflammatory drug (NSAID) for the treatment of postoperative pain and inflammation in patients who have undergone cataract extraction.
Development timeline for Xibrom
| Date | Article |
|---|---|
| Jan 27, 2006 | Approval Xibrom - ISTA Pharmaceuticals, Inc. - New Indication Approved |
| Mar 24, 2005 | Approval Xibrom ISTA Pharmaceuticals, Inc. - Treatment for Ocular Inflammation Following Cataract Surgery |
| Jul 26, 2004 | FDA Accepts ISTA Pharmaceuticals' New Drug Application for Xibrom |
| May 25, 2004 | ISTA Pharmaceuticals Announces Submission of Xibrom NDA to the FDA |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.